| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 220 | 2024 | 5034 | 13.380 |
Why?
|
| Cardiomyopathy, Dilated | 13 | 2023 | 851 | 3.030 |
Why?
|
| Genome-Wide Association Study | 100 | 2023 | 12261 | 2.840 |
Why?
|
| Genetic Predisposition to Disease | 87 | 2024 | 17446 | 2.750 |
Why?
|
| Polymorphism, Single Nucleotide | 80 | 2023 | 15519 | 2.700 |
Why?
|
| Heart Conduction System | 23 | 2018 | 1047 | 2.560 |
Why?
|
| Electrocardiography | 55 | 2024 | 6442 | 2.140 |
Why?
|
| Long QT Syndrome | 16 | 2022 | 453 | 1.880 |
Why?
|
| Heart Atria | 20 | 2023 | 1357 | 1.870 |
Why?
|
| Multifactorial Inheritance | 14 | 2023 | 1194 | 1.820 |
Why?
|
| Genetic Variation | 33 | 2022 | 6544 | 1.710 |
Why?
|
| Muscle Proteins | 12 | 2020 | 1159 | 1.700 |
Why?
|
| Homeodomain Proteins | 12 | 2023 | 2421 | 1.690 |
Why?
|
| Chromosomes, Human, Pair 4 | 10 | 2017 | 374 | 1.590 |
Why?
|
| Genetic Loci | 30 | 2024 | 2575 | 1.580 |
Why?
|
| Aortic Aneurysm, Thoracic | 9 | 2023 | 686 | 1.570 |
Why?
|
| Heart Failure | 40 | 2024 | 10900 | 1.440 |
Why?
|
| Cardiomyopathies | 16 | 2023 | 1912 | 1.420 |
Why?
|
| Arrhythmias, Cardiac | 20 | 2023 | 2268 | 1.420 |
Why?
|
| Death, Sudden, Cardiac | 19 | 2022 | 1541 | 1.390 |
Why?
|
| Quantitative Trait Loci | 15 | 2023 | 2019 | 1.290 |
Why?
|
| Coronary Artery Disease | 22 | 2024 | 6487 | 1.280 |
Why?
|
| Stroke | 36 | 2023 | 9981 | 1.270 |
Why?
|
| Cardiomyopathy, Restrictive | 3 | 2018 | 60 | 1.250 |
Why?
|
| Aortic Aneurysm | 5 | 2023 | 643 | 1.230 |
Why?
|
| Genetic Association Studies | 14 | 2021 | 2703 | 1.190 |
Why?
|
| Sodium Channels | 7 | 2022 | 349 | 1.110 |
Why?
|
| Humans | 400 | 2024 | 744343 | 1.060 |
Why?
|
| Myocardium | 19 | 2023 | 4776 | 1.040 |
Why?
|
| Potassium Channels, Voltage-Gated | 6 | 2010 | 142 | 0.980 |
Why?
|
| Aorta | 10 | 2023 | 2061 | 0.960 |
Why?
|
| Defibrillators, Implantable | 12 | 2016 | 1440 | 0.920 |
Why?
|
| Potassium Channels | 7 | 2020 | 563 | 0.910 |
Why?
|
| Models, Cardiovascular | 4 | 2022 | 996 | 0.890 |
Why?
|
| Aortic Diseases | 3 | 2023 | 742 | 0.870 |
Why?
|
| Myocytes, Cardiac | 10 | 2023 | 1637 | 0.860 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 3 | 2015 | 45 | 0.860 |
Why?
|
| Connexin 43 | 5 | 2018 | 207 | 0.850 |
Why?
|
| Middle Aged | 178 | 2024 | 213383 | 0.850 |
Why?
|
| Cardiomyopathy, Hypertrophic | 6 | 2022 | 1265 | 0.840 |
Why?
|
| Anti-Arrhythmia Agents | 8 | 2022 | 789 | 0.840 |
Why?
|
| Cardiovascular Diseases | 23 | 2024 | 15165 | 0.830 |
Why?
|
| Aged | 157 | 2024 | 163280 | 0.810 |
Why?
|
| Risk Factors | 123 | 2024 | 72290 | 0.800 |
Why?
|
| Risk Assessment | 46 | 2023 | 23338 | 0.790 |
Why?
|
| Biological Specimen Banks | 9 | 2022 | 711 | 0.790 |
Why?
|
| Male | 221 | 2024 | 350118 | 0.780 |
Why?
|
| Biology | 1 | 2023 | 294 | 0.760 |
Why?
|
| Female | 225 | 2024 | 380194 | 0.750 |
Why?
|
| Catheter Ablation | 17 | 2020 | 2758 | 0.730 |
Why?
|
| Single-Cell Analysis | 6 | 2023 | 2183 | 0.720 |
Why?
|
| Genetic Testing | 11 | 2023 | 3444 | 0.720 |
Why?
|
| Ion Channels | 6 | 2017 | 1056 | 0.710 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 546 | 0.700 |
Why?
|
| Atrioventricular Node | 4 | 2018 | 182 | 0.700 |
Why?
|
| Mutation | 32 | 2022 | 29786 | 0.690 |
Why?
|
| Aneurysm | 1 | 2022 | 339 | 0.670 |
Why?
|
| Aorta, Thoracic | 2 | 2023 | 1082 | 0.660 |
Why?
|
| T-Box Domain Proteins | 4 | 2017 | 471 | 0.660 |
Why?
|
| Heart Rate | 14 | 2023 | 4091 | 0.660 |
Why?
|
| Peptide Hydrolases | 1 | 2022 | 634 | 0.660 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2022 | 581 | 0.650 |
Why?
|
| American Heart Association | 7 | 2019 | 1056 | 0.640 |
Why?
|
| Pedigree | 13 | 2023 | 4644 | 0.630 |
Why?
|
| Connexins | 4 | 2017 | 357 | 0.620 |
Why?
|
| KCNQ1 Potassium Channel | 5 | 2010 | 104 | 0.620 |
Why?
|
| Phenotype | 32 | 2023 | 16365 | 0.620 |
Why?
|
| Transcription Factors | 13 | 2023 | 12208 | 0.610 |
Why?
|
| Myocardial Ischemia | 3 | 2023 | 2148 | 0.610 |
Why?
|
| Ion Channel Gating | 4 | 2018 | 437 | 0.600 |
Why?
|
| Action Potentials | 10 | 2022 | 1806 | 0.600 |
Why?
|
| Mitral Valve Prolapse | 4 | 2022 | 231 | 0.590 |
Why?
|
| GATA6 Transcription Factor | 1 | 2016 | 50 | 0.570 |
Why?
|
| Transcription Factor AP-2 | 1 | 2016 | 82 | 0.570 |
Why?
|
| Genotype | 27 | 2023 | 12951 | 0.570 |
Why?
|
| Gene Regulatory Networks | 4 | 2024 | 1708 | 0.560 |
Why?
|
| Gene Expression Profiling | 12 | 2023 | 9438 | 0.560 |
Why?
|
| Heart Ventricles | 11 | 2022 | 3821 | 0.540 |
Why?
|
| Epigenesis, Genetic | 7 | 2021 | 3647 | 0.540 |
Why?
|
| Enhancer Elements, Genetic | 5 | 2020 | 1341 | 0.540 |
Why?
|
| Atrioventricular Block | 1 | 2017 | 120 | 0.530 |
Why?
|
| Gene Frequency | 15 | 2022 | 3588 | 0.530 |
Why?
|
| Genome, Human | 13 | 2022 | 4420 | 0.530 |
Why?
|
| Atrial Function | 2 | 2018 | 107 | 0.520 |
Why?
|
| Natriuretic Peptide, Brain | 9 | 2023 | 1573 | 0.520 |
Why?
|
| Mutation, Missense | 7 | 2018 | 2564 | 0.510 |
Why?
|
| Myocardial Infarction | 16 | 2024 | 11727 | 0.510 |
Why?
|
| Chromosome Mapping | 8 | 2022 | 4740 | 0.510 |
Why?
|
| Genomics | 11 | 2024 | 5720 | 0.510 |
Why?
|
| Brugada Syndrome | 4 | 2022 | 97 | 0.510 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 935 | 0.510 |
Why?
|
| Bradycardia | 3 | 2024 | 307 | 0.490 |
Why?
|
| Calcium Channels | 13 | 1996 | 622 | 0.490 |
Why?
|
| Linkage Disequilibrium | 11 | 2022 | 1997 | 0.490 |
Why?
|
| Transcription, Genetic | 7 | 2022 | 7722 | 0.480 |
Why?
|
| Cardiology | 8 | 2019 | 1668 | 0.480 |
Why?
|
| Zebrafish | 15 | 2023 | 2994 | 0.470 |
Why?
|
| Atrial Natriuretic Factor | 3 | 2019 | 393 | 0.470 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2016 | 488 | 0.470 |
Why?
|
| Ventricular Fibrillation | 6 | 2016 | 538 | 0.470 |
Why?
|
| Cell Nucleus | 2 | 2022 | 2969 | 0.470 |
Why?
|
| Incidence | 48 | 2023 | 20947 | 0.460 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2013 | 845 | 0.460 |
Why?
|
| Aortic Valve Stenosis | 2 | 2024 | 1965 | 0.450 |
Why?
|
| Lipoprotein(a) | 3 | 2024 | 435 | 0.450 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2016 | 478 | 0.450 |
Why?
|
| Models, Genetic | 7 | 2023 | 3494 | 0.450 |
Why?
|
| Genetic Markers | 4 | 2014 | 2634 | 0.450 |
Why?
|
| Mosaicism | 2 | 2021 | 441 | 0.450 |
Why?
|
| Atherosclerosis | 8 | 2023 | 3445 | 0.440 |
Why?
|
| Sequence Analysis, DNA | 6 | 2020 | 4803 | 0.440 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 3 | 2010 | 161 | 0.440 |
Why?
|
| Animals | 68 | 2023 | 168757 | 0.440 |
Why?
|
| Chromatin | 7 | 2024 | 2934 | 0.430 |
Why?
|
| Heart Block | 2 | 2013 | 410 | 0.430 |
Why?
|
| Case-Control Studies | 26 | 2023 | 21746 | 0.420 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 3 | 2010 | 70 | 0.420 |
Why?
|
| Warfarin | 1 | 2021 | 1496 | 0.420 |
Why?
|
| Penetrance | 4 | 2023 | 381 | 0.420 |
Why?
|
| Cohort Studies | 46 | 2023 | 40561 | 0.410 |
Why?
|
| Alleles | 15 | 2022 | 6933 | 0.410 |
Why?
|
| Mendelian Randomization Analysis | 7 | 2022 | 967 | 0.410 |
Why?
|
| Proportional Hazards Models | 33 | 2021 | 12354 | 0.400 |
Why?
|
| Sepsis | 2 | 2023 | 2593 | 0.400 |
Why?
|
| Ventricular Remodeling | 6 | 2022 | 1224 | 0.400 |
Why?
|
| Tachycardia, Ventricular | 7 | 2016 | 1273 | 0.400 |
Why?
|
| Anticoagulants | 5 | 2021 | 4599 | 0.400 |
Why?
|
| Heart Diseases | 8 | 2022 | 2788 | 0.390 |
Why?
|
| Endothelial Cells | 8 | 2023 | 3479 | 0.390 |
Why?
|
| Amino Acids | 1 | 2016 | 1736 | 0.370 |
Why?
|
| Procainamide | 1 | 2010 | 61 | 0.370 |
Why?
|
| Cardiac Electrophysiology | 1 | 2010 | 49 | 0.370 |
Why?
|
| Polymorphism, Genetic | 7 | 2023 | 4328 | 0.370 |
Why?
|
| Stroke Volume | 12 | 2023 | 5007 | 0.360 |
Why?
|
| Genetic Linkage | 5 | 2015 | 2421 | 0.360 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 5 | 2021 | 314 | 0.360 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2021 | 3537 | 0.350 |
Why?
|
| Adult | 76 | 2024 | 214055 | 0.350 |
Why?
|
| Electromagnetic Fields | 1 | 2011 | 298 | 0.340 |
Why?
|
| Electrocardiography, Ambulatory | 4 | 2022 | 585 | 0.340 |
Why?
|
| Age of Onset | 9 | 2022 | 3271 | 0.340 |
Why?
|
| Microfilament Proteins | 4 | 2020 | 1152 | 0.340 |
Why?
|
| Aged, 80 and over | 46 | 2022 | 57776 | 0.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2023 | 11725 | 0.330 |
Why?
|
| Mice | 27 | 2023 | 81183 | 0.330 |
Why?
|
| Lipids | 5 | 2023 | 3305 | 0.330 |
Why?
|
| RNA-Binding Proteins | 3 | 2013 | 1903 | 0.320 |
Why?
|
| Muscle, Smooth, Vascular | 6 | 2023 | 1504 | 0.320 |
Why?
|
| Equipment Failure Analysis | 1 | 2011 | 868 | 0.320 |
Why?
|
| Amiodarone | 1 | 2010 | 212 | 0.320 |
Why?
|
| Electric Countershock | 6 | 2016 | 534 | 0.310 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 4 | 2014 | 493 | 0.310 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2014 | 531 | 0.310 |
Why?
|
| Heterozygote | 6 | 2022 | 2804 | 0.310 |
Why?
|
| Haplotypes | 8 | 2022 | 2779 | 0.310 |
Why?
|
| Electric Power Supplies | 2 | 2011 | 99 | 0.310 |
Why?
|
| Atrial Flutter | 4 | 2015 | 263 | 0.310 |
Why?
|
| RNA Splice Sites | 2 | 2023 | 209 | 0.300 |
Why?
|
| Exercise | 2 | 2023 | 5615 | 0.300 |
Why?
|
| Carrier Proteins | 4 | 2023 | 5021 | 0.300 |
Why?
|
| Repressor Proteins | 2 | 2018 | 3023 | 0.290 |
Why?
|
| Massachusetts | 18 | 2020 | 8663 | 0.290 |
Why?
|
| Tachycardia | 1 | 2009 | 619 | 0.290 |
Why?
|
| Prevalence | 21 | 2023 | 15226 | 0.290 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2016 | 3597 | 0.290 |
Why?
|
| Heart | 9 | 2023 | 4467 | 0.290 |
Why?
|
| Aspergillus niger | 1 | 2006 | 17 | 0.280 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2023 | 687 | 0.270 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2022 | 373 | 0.270 |
Why?
|
| Epistasis, Genetic | 3 | 2017 | 365 | 0.270 |
Why?
|
| Hypertension | 11 | 2022 | 8480 | 0.270 |
Why?
|
| Emergency Treatment | 1 | 2010 | 517 | 0.270 |
Why?
|
| Databases, Genetic | 7 | 2021 | 1783 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 8 | 2020 | 7279 | 0.270 |
Why?
|
| Multivariate Analysis | 15 | 2017 | 12245 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2006 | 287 | 0.260 |
Why?
|
| Heart Defects, Congenital | 1 | 2022 | 4584 | 0.260 |
Why?
|
| Aging | 8 | 2021 | 8664 | 0.260 |
Why?
|
| Predictive Value of Tests | 14 | 2023 | 15076 | 0.260 |
Why?
|
| Europe | 7 | 2022 | 3339 | 0.260 |
Why?
|
| RNA Splicing | 4 | 2023 | 907 | 0.260 |
Why?
|
| RNA, Nuclear | 2 | 2022 | 30 | 0.260 |
Why?
|
| Brain Ischemia | 5 | 2023 | 3265 | 0.260 |
Why?
|
| Body Height | 3 | 2022 | 1577 | 0.250 |
Why?
|
| United States | 44 | 2023 | 69872 | 0.250 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 1861 | 0.250 |
Why?
|
| Critical Pathways | 3 | 2023 | 476 | 0.250 |
Why?
|
| Gene Expression Regulation | 8 | 2021 | 12072 | 0.250 |
Why?
|
| Disease Management | 4 | 2020 | 2459 | 0.250 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 8949 | 0.250 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 1801 | 0.240 |
Why?
|
| Equipment Failure | 5 | 2011 | 578 | 0.240 |
Why?
|
| Adenosine | 1 | 2009 | 825 | 0.240 |
Why?
|
| Body Surface Potential Mapping | 4 | 2020 | 238 | 0.240 |
Why?
|
| Longitudinal Studies | 16 | 2024 | 13989 | 0.240 |
Why?
|
| Blood Proteins | 2 | 2020 | 1124 | 0.240 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2021 | 859 | 0.240 |
Why?
|
| Aspergillosis | 1 | 2006 | 235 | 0.240 |
Why?
|
| Terminology as Topic | 2 | 2016 | 1547 | 0.240 |
Why?
|
| Gene Expression | 5 | 2020 | 7799 | 0.240 |
Why?
|
| C-Reactive Protein | 4 | 2014 | 3778 | 0.240 |
Why?
|
| Prognosis | 26 | 2024 | 29063 | 0.240 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2020 | 365 | 0.230 |
Why?
|
| Bundle-Branch Block | 1 | 2005 | 270 | 0.230 |
Why?
|
| Follow-Up Studies | 31 | 2021 | 39050 | 0.230 |
Why?
|
| Postoperative Complications | 6 | 2021 | 15295 | 0.230 |
Why?
|
| RNA, Small Nuclear | 1 | 2023 | 65 | 0.230 |
Why?
|
| Candidiasis | 1 | 2006 | 366 | 0.230 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 5853 | 0.230 |
Why?
|
| Endophenotypes | 2 | 2022 | 250 | 0.230 |
Why?
|
| Ventricular Function, Left | 7 | 2023 | 3670 | 0.230 |
Why?
|
| Pharmacogenetics | 4 | 2016 | 675 | 0.220 |
Why?
|
| Physical Chromosome Mapping | 1 | 2003 | 183 | 0.220 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2017 | 1676 | 0.220 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2023 | 27 | 0.220 |
Why?
|
| Cryosurgery | 2 | 2018 | 453 | 0.220 |
Why?
|
| Retrospective Studies | 26 | 2023 | 77449 | 0.220 |
Why?
|
| DNA Methylation | 4 | 2021 | 4286 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2023 | 35421 | 0.210 |
Why?
|
| Heart Transplantation | 4 | 2015 | 3110 | 0.210 |
Why?
|
| Time Factors | 27 | 2021 | 40075 | 0.210 |
Why?
|
| Anticholesteremic Agents | 2 | 2020 | 979 | 0.210 |
Why?
|
| Electronic Health Records | 6 | 2023 | 4468 | 0.210 |
Why?
|
| Body Weights and Measures | 1 | 2022 | 211 | 0.210 |
Why?
|
| Zebrafish Proteins | 3 | 2014 | 1005 | 0.210 |
Why?
|
| RNA, Messenger | 7 | 2023 | 13033 | 0.210 |
Why?
|
| Dilatation | 1 | 2023 | 291 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2003 | 380 | 0.210 |
Why?
|
| Thyroid Gland | 2 | 2019 | 1173 | 0.200 |
Why?
|
| Flecainide | 1 | 2022 | 42 | 0.200 |
Why?
|
| Tail | 1 | 2022 | 97 | 0.200 |
Why?
|
| Genetics, Population | 3 | 2021 | 934 | 0.200 |
Why?
|
| Osteopontin | 1 | 2023 | 296 | 0.200 |
Why?
|
| Base Sequence | 8 | 2020 | 12797 | 0.200 |
Why?
|
| Macrophages | 3 | 2023 | 5655 | 0.200 |
Why?
|
| Channelopathies | 2 | 2011 | 32 | 0.200 |
Why?
|
| Advisory Committees | 4 | 2019 | 775 | 0.200 |
Why?
|
| MicroRNAs | 5 | 2018 | 3752 | 0.200 |
Why?
|
| Epigenomics | 4 | 2023 | 903 | 0.200 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2013 | 224 | 0.200 |
Why?
|
| Heart Valves | 4 | 2019 | 291 | 0.190 |
Why?
|
| Age Factors | 17 | 2021 | 18370 | 0.190 |
Why?
|
| Body Mass Index | 10 | 2023 | 12720 | 0.190 |
Why?
|
| Genetic Techniques | 1 | 2024 | 435 | 0.190 |
Why?
|
| Open Reading Frames | 2 | 2021 | 810 | 0.190 |
Why?
|
| Confidence Intervals | 7 | 2016 | 2971 | 0.190 |
Why?
|
| Receptors, Cell Surface | 3 | 2018 | 2866 | 0.190 |
Why?
|
| Organ Specificity | 3 | 2022 | 2008 | 0.190 |
Why?
|
| Family | 4 | 2017 | 3147 | 0.190 |
Why?
|
| Sequence Analysis, RNA | 3 | 2023 | 2012 | 0.190 |
Why?
|
| Carbachol | 1 | 2020 | 226 | 0.190 |
Why?
|
| Cholesterol, LDL | 5 | 2022 | 2356 | 0.190 |
Why?
|
| Myofibroblasts | 1 | 2022 | 222 | 0.180 |
Why?
|
| Calcium | 5 | 2023 | 5756 | 0.180 |
Why?
|
| Cells, Cultured | 7 | 2022 | 19229 | 0.180 |
Why?
|
| Obesity | 7 | 2022 | 12745 | 0.180 |
Why?
|
| Intra-Abdominal Fat | 2 | 2023 | 591 | 0.180 |
Why?
|
| Venous Thrombosis | 2 | 2020 | 1239 | 0.180 |
Why?
|
| Aortic Coarctation | 1 | 2022 | 281 | 0.180 |
Why?
|
| Prosthesis-Related Infections | 1 | 2006 | 538 | 0.180 |
Why?
|
| Hemorrhage | 3 | 2022 | 3461 | 0.180 |
Why?
|
| Dyslipidemias | 2 | 2020 | 849 | 0.180 |
Why?
|
| Hyperthyroidism | 2 | 2019 | 295 | 0.180 |
Why?
|
| Japan | 2 | 2014 | 1360 | 0.180 |
Why?
|
| Factor XI | 1 | 2019 | 26 | 0.180 |
Why?
|
| Hypothyroidism | 3 | 2019 | 658 | 0.180 |
Why?
|
| Fibrosis | 5 | 2023 | 2029 | 0.180 |
Why?
|
| Prospective Studies | 27 | 2022 | 53288 | 0.170 |
Why?
|
| Chromosomes, Human, X | 1 | 2021 | 296 | 0.170 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2017 | 170 | 0.170 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 173 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 3 | 2022 | 2007 | 0.170 |
Why?
|
| beta-Globins | 1 | 2019 | 113 | 0.170 |
Why?
|
| Gene Knockout Techniques | 1 | 2022 | 809 | 0.170 |
Why?
|
| Lymphocyte Subsets | 1 | 2020 | 315 | 0.170 |
Why?
|
| Galectin 3 | 2 | 2014 | 227 | 0.170 |
Why?
|
| Catalytic Domain | 1 | 2021 | 698 | 0.170 |
Why?
|
| Biomedical Research | 3 | 2014 | 3309 | 0.170 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2020 | 179 | 0.160 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2019 | 794 | 0.160 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 1107 | 0.160 |
Why?
|
| Vitamin K | 1 | 2021 | 295 | 0.160 |
Why?
|
| Disease Models, Animal | 10 | 2023 | 18029 | 0.160 |
Why?
|
| Thyrotropin | 2 | 2019 | 849 | 0.160 |
Why?
|
| Heart Arrest | 3 | 2024 | 1470 | 0.160 |
Why?
|
| Sex Characteristics | 2 | 2020 | 2585 | 0.160 |
Why?
|
| Endopeptidases | 1 | 2022 | 772 | 0.160 |
Why?
|
| Ventricular Function, Right | 1 | 2022 | 591 | 0.160 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2022 | 644 | 0.160 |
Why?
|
| Survival Rate | 10 | 2021 | 12788 | 0.160 |
Why?
|
| Proteomics | 4 | 2024 | 3638 | 0.160 |
Why?
|
| Meta-Analysis as Topic | 6 | 2017 | 1344 | 0.160 |
Why?
|
| Mollusk Venoms | 2 | 1994 | 19 | 0.160 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 936 | 0.160 |
Why?
|
| Odds Ratio | 9 | 2020 | 9849 | 0.160 |
Why?
|
| Administration, Oral | 3 | 2021 | 3913 | 0.150 |
Why?
|
| Caveolin 2 | 1 | 2017 | 25 | 0.150 |
Why?
|
| Protein Kinase C-alpha | 1 | 2018 | 112 | 0.150 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 1671 | 0.150 |
Why?
|
| Forecasting | 2 | 2019 | 2951 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2015 | 924 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 9 | 2021 | 21827 | 0.150 |
Why?
|
| Pericytes | 1 | 2020 | 292 | 0.150 |
Why?
|
| Microvessels | 1 | 2021 | 544 | 0.150 |
Why?
|
| Electronic Prescribing | 1 | 2018 | 121 | 0.150 |
Why?
|
| Biophysical Phenomena | 1 | 2018 | 327 | 0.150 |
Why?
|
| Disability Evaluation | 2 | 2016 | 1827 | 0.150 |
Why?
|
| Societies, Medical | 3 | 2019 | 3743 | 0.150 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 551 | 0.150 |
Why?
|
| Quality Control | 3 | 2021 | 841 | 0.150 |
Why?
|
| Alternative Splicing | 3 | 2023 | 1117 | 0.140 |
Why?
|
| Registries | 5 | 2021 | 8089 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2015 | 1518 | 0.140 |
Why?
|
| Peptide Fragments | 5 | 2023 | 5097 | 0.140 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2016 | 58 | 0.140 |
Why?
|
| Germ-Line Mutation | 2 | 2021 | 1788 | 0.140 |
Why?
|
| Electrophysiological Phenomena | 1 | 2018 | 315 | 0.140 |
Why?
|
| Homozygote | 3 | 2018 | 1785 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2018 | 3920 | 0.140 |
Why?
|
| Recurrence | 9 | 2020 | 8340 | 0.140 |
Why?
|
| Amino Acid Sequence | 12 | 2017 | 13815 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 1655 | 0.130 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 379 | 0.130 |
Why?
|
| Disease Susceptibility | 3 | 2022 | 1782 | 0.130 |
Why?
|
| Liver | 4 | 2021 | 7474 | 0.130 |
Why?
|
| Caveolin 1 | 1 | 2017 | 263 | 0.130 |
Why?
|
| Sex Factors | 8 | 2020 | 10397 | 0.130 |
Why?
|
| Macular Degeneration | 1 | 2023 | 980 | 0.130 |
Why?
|
| Deoxyribonucleases | 1 | 2016 | 214 | 0.130 |
Why?
|
| Statistics as Topic | 2 | 2019 | 2373 | 0.130 |
Why?
|
| Cilia | 1 | 2019 | 466 | 0.130 |
Why?
|
| Adenine | 1 | 2020 | 936 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 1 | 2022 | 1351 | 0.130 |
Why?
|
| Technology Transfer | 1 | 2015 | 44 | 0.130 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2019 | 342 | 0.130 |
Why?
|
| Office Visits | 1 | 2019 | 598 | 0.130 |
Why?
|
| KCNQ Potassium Channels | 2 | 2004 | 18 | 0.120 |
Why?
|
| DNA | 6 | 2022 | 7301 | 0.120 |
Why?
|
| Animals, Genetically Modified | 2 | 2017 | 1549 | 0.120 |
Why?
|
| Primary Health Care | 5 | 2023 | 4558 | 0.120 |
Why?
|
| Calcium Channel Blockers | 3 | 1996 | 690 | 0.120 |
Why?
|
| Treatment Outcome | 20 | 2021 | 63114 | 0.120 |
Why?
|
| Motor Activity | 2 | 2016 | 2714 | 0.120 |
Why?
|
| Mutagenesis | 4 | 2021 | 1266 | 0.120 |
Why?
|
| Lod Score | 2 | 2006 | 614 | 0.120 |
Why?
|
| Aortic Valve | 2 | 2018 | 1922 | 0.120 |
Why?
|
| Ablation Techniques | 1 | 2017 | 249 | 0.120 |
Why?
|
| Voltage-Sensitive Dye Imaging | 1 | 2013 | 31 | 0.120 |
Why?
|
| Heart Valve Diseases | 2 | 2019 | 1073 | 0.120 |
Why?
|
| Echocardiography | 4 | 2022 | 5102 | 0.120 |
Why?
|
| Software | 3 | 2023 | 4443 | 0.120 |
Why?
|
| omega-Conotoxins | 1 | 1993 | 18 | 0.120 |
Why?
|
| Embolism | 1 | 2017 | 408 | 0.120 |
Why?
|
| Neurotoxins | 1 | 1994 | 237 | 0.120 |
Why?
|
| Health Status | 3 | 2020 | 4034 | 0.120 |
Why?
|
| Cell Line | 5 | 2022 | 15997 | 0.120 |
Why?
|
| Heredity | 1 | 2014 | 154 | 0.120 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 850 | 0.120 |
Why?
|
| HEK293 Cells | 2 | 2021 | 4204 | 0.110 |
Why?
|
| Erythrocytes | 2 | 2021 | 2455 | 0.110 |
Why?
|
| Heart Failure, Systolic | 1 | 2015 | 126 | 0.110 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2020 | 828 | 0.110 |
Why?
|
| Evidence-Based Medicine | 3 | 2014 | 3610 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2015 | 2073 | 0.110 |
Why?
|
| Patient Care Management | 1 | 2016 | 306 | 0.110 |
Why?
|
| Adipocytes | 1 | 2020 | 1184 | 0.110 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 728 | 0.110 |
Why?
|
| Electrophysiology | 5 | 2009 | 1308 | 0.110 |
Why?
|
| Heart Murmurs | 2 | 2013 | 94 | 0.110 |
Why?
|
| Conserved Sequence | 1 | 2016 | 1202 | 0.110 |
Why?
|
| Genetics | 1 | 2013 | 112 | 0.110 |
Why?
|
| Genealogy and Heraldry | 1 | 2012 | 28 | 0.110 |
Why?
|
| Age Distribution | 6 | 2016 | 2902 | 0.110 |
Why?
|
| Lamin Type A | 2 | 2022 | 190 | 0.110 |
Why?
|
| Fibroblasts | 2 | 2021 | 4161 | 0.110 |
Why?
|
| Medical Order Entry Systems | 1 | 2018 | 545 | 0.110 |
Why?
|
| Magnesium Deficiency | 1 | 2012 | 47 | 0.110 |
Why?
|
| Disease | 1 | 2018 | 680 | 0.110 |
Why?
|
| Patch-Clamp Techniques | 2 | 2018 | 964 | 0.110 |
Why?
|
| Comorbidity | 8 | 2023 | 10388 | 0.110 |
Why?
|
| Myocarditis | 1 | 2020 | 771 | 0.110 |
Why?
|
| Desmosomes | 2 | 2010 | 73 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2021 | 880 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2020 | 1058 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2015 | 689 | 0.110 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2016 | 604 | 0.110 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2015 | 263 | 0.110 |
Why?
|
| DNA Helicases | 1 | 2018 | 859 | 0.110 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2013 | 176 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2020 | 1157 | 0.110 |
Why?
|
| Introns | 2 | 2018 | 991 | 0.110 |
Why?
|
| Piperidines | 1 | 2020 | 1602 | 0.100 |
Why?
|
| Arginine | 1 | 2016 | 944 | 0.100 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 3508 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 4186 | 0.100 |
Why?
|
| Cricetulus | 1 | 2014 | 816 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2022 | 2635 | 0.100 |
Why?
|
| Systole | 3 | 2015 | 958 | 0.100 |
Why?
|
| Haploinsufficiency | 1 | 2014 | 328 | 0.100 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 15540 | 0.100 |
Why?
|
| Signal Transduction | 6 | 2022 | 23403 | 0.100 |
Why?
|
| Proteome | 1 | 2022 | 1799 | 0.100 |
Why?
|
| Transaminases | 1 | 2012 | 199 | 0.100 |
Why?
|
| Young Adult | 12 | 2023 | 56430 | 0.100 |
Why?
|
| Birth Weight | 1 | 2020 | 2069 | 0.100 |
Why?
|
| Mammals | 2 | 2016 | 1143 | 0.100 |
Why?
|
| Logistic Models | 8 | 2017 | 13408 | 0.100 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 2214 | 0.100 |
Why?
|
| Primary Prevention | 3 | 2023 | 1167 | 0.100 |
Why?
|
| Telomere | 1 | 2017 | 910 | 0.100 |
Why?
|
| Oocytes | 4 | 2021 | 1187 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 3508 | 0.100 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2011 | 31 | 0.100 |
Why?
|
| Reproducibility of Results | 12 | 2022 | 19905 | 0.100 |
Why?
|
| Apolipoproteins B | 2 | 2024 | 374 | 0.100 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 3966 | 0.100 |
Why?
|
| Morbidity | 3 | 2019 | 1769 | 0.100 |
Why?
|
| CHO Cells | 1 | 2014 | 1406 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2020 | 2240 | 0.100 |
Why?
|
| Resistin | 1 | 2011 | 170 | 0.100 |
Why?
|
| Renin-Angiotensin System | 2 | 2014 | 759 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 1028 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2018 | 1359 | 0.090 |
Why?
|
| Clothing | 1 | 2011 | 92 | 0.090 |
Why?
|
| Coronary Artery Bypass | 2 | 2011 | 2289 | 0.090 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2011 | 1018 | 0.090 |
Why?
|
| Genetic Research | 1 | 2011 | 174 | 0.090 |
Why?
|
| Retina | 1 | 2021 | 2616 | 0.090 |
Why?
|
| Disease Progression | 6 | 2016 | 13284 | 0.090 |
Why?
|
| Algorithms | 4 | 2021 | 13881 | 0.090 |
Why?
|
| G Protein-Coupled Inwardly-Rectifying Potassium Channels | 1 | 2010 | 64 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 1723 | 0.090 |
Why?
|
| Adolescent | 12 | 2022 | 85781 | 0.090 |
Why?
|
| Denmark | 3 | 2021 | 738 | 0.090 |
Why?
|
| Electromagnetic Phenomena | 1 | 2011 | 161 | 0.090 |
Why?
|
| Mass Screening | 3 | 2022 | 5255 | 0.090 |
Why?
|
| Thromboembolism | 4 | 2021 | 986 | 0.090 |
Why?
|
| Mice, Knockout | 6 | 2020 | 14557 | 0.090 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 712 | 0.090 |
Why?
|
| Energy Intake | 1 | 2017 | 2148 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 5867 | 0.090 |
Why?
|
| Chromosomes | 2 | 2024 | 596 | 0.090 |
Why?
|
| Histones | 2 | 2018 | 2599 | 0.090 |
Why?
|
| Duffy Blood-Group System | 1 | 2009 | 58 | 0.090 |
Why?
|
| Guideline Adherence | 2 | 2018 | 2266 | 0.090 |
Why?
|
| Immediate-Early Proteins | 1 | 2012 | 453 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2022 | 20129 | 0.090 |
Why?
|
| Veterans | 1 | 2023 | 2519 | 0.090 |
Why?
|
| Leukocytes | 1 | 2017 | 2043 | 0.090 |
Why?
|
| Adipose Tissue | 3 | 2023 | 3279 | 0.090 |
Why?
|
| Pneumonia | 1 | 2021 | 2133 | 0.090 |
Why?
|
| Magnesium | 1 | 2012 | 813 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2727 | 0.080 |
Why?
|
| Muscle Cells | 1 | 2010 | 197 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2020 | 4217 | 0.080 |
Why?
|
| Homeostasis | 1 | 2020 | 3340 | 0.080 |
Why?
|
| Oxygen Consumption | 2 | 2024 | 1869 | 0.080 |
Why?
|
| Linear Models | 4 | 2014 | 5952 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 9734 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3703 | 0.080 |
Why?
|
| Patient Admission | 1 | 2016 | 1380 | 0.080 |
Why?
|
| Sample Size | 2 | 2022 | 845 | 0.080 |
Why?
|
| INDEL Mutation | 2 | 2021 | 279 | 0.080 |
Why?
|
| Tandem Repeat Sequences | 1 | 2009 | 185 | 0.080 |
Why?
|
| Policy Making | 1 | 2012 | 554 | 0.080 |
Why?
|
| Thyroid Function Tests | 2 | 2019 | 286 | 0.080 |
Why?
|
| Protein Transport | 1 | 2014 | 1988 | 0.080 |
Why?
|
| Syndrome | 3 | 2017 | 3251 | 0.080 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 1970 | 0.080 |
Why?
|
| Hospitals, Urban | 1 | 2010 | 499 | 0.080 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2008 | 127 | 0.080 |
Why?
|
| Marfan Syndrome | 1 | 2010 | 240 | 0.080 |
Why?
|
| Metabolomics | 1 | 2016 | 1484 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 3255 | 0.080 |
Why?
|
| Situs Inversus | 1 | 2007 | 64 | 0.080 |
Why?
|
| Rest | 1 | 2012 | 901 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2011 | 1588 | 0.080 |
Why?
|
| Mortality | 2 | 2016 | 2864 | 0.080 |
Why?
|
| DNA-Binding Proteins | 3 | 2020 | 9648 | 0.080 |
Why?
|
| Ultrasonography | 4 | 2014 | 5985 | 0.080 |
Why?
|
| New York | 1 | 2010 | 886 | 0.070 |
Why?
|
| Mass Spectrometry | 2 | 2016 | 2203 | 0.070 |
Why?
|
| Desmocollins | 1 | 2006 | 12 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 617 | 0.070 |
Why?
|
| Sodium Channel Blockers | 2 | 2022 | 176 | 0.070 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2007 | 137 | 0.070 |
Why?
|
| Pulmonary Embolism | 3 | 2020 | 2376 | 0.070 |
Why?
|
| Xenopus | 5 | 1996 | 712 | 0.070 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 795 | 0.070 |
Why?
|
| Cross-Sectional Studies | 7 | 2022 | 25043 | 0.070 |
Why?
|
| Sodium | 2 | 2022 | 1623 | 0.070 |
Why?
|
| Body Composition | 1 | 2016 | 2401 | 0.070 |
Why?
|
| Triglycerides | 1 | 2014 | 2454 | 0.070 |
Why?
|
| Heart Injuries | 1 | 2008 | 210 | 0.070 |
Why?
|
| Friedreich Ataxia | 1 | 2007 | 76 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2017 | 2899 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 3617 | 0.070 |
Why?
|
| Single-Blind Method | 1 | 2010 | 1590 | 0.070 |
Why?
|
| Sex Distribution | 3 | 2016 | 2297 | 0.070 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2006 | 150 | 0.070 |
Why?
|
| Adiponectin | 1 | 2011 | 1100 | 0.070 |
Why?
|
| Aging, Premature | 1 | 2005 | 47 | 0.070 |
Why?
|
| Adiposity | 3 | 2023 | 1807 | 0.070 |
Why?
|
| Immunoassay | 2 | 2009 | 752 | 0.070 |
Why?
|
| Kidney | 1 | 2021 | 7186 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 12959 | 0.070 |
Why?
|
| Peptides | 2 | 1994 | 4409 | 0.060 |
Why?
|
| Pulmonary Veins | 1 | 2011 | 761 | 0.060 |
Why?
|
| Random Allocation | 2 | 2022 | 2429 | 0.060 |
Why?
|
| CpG Islands | 2 | 2021 | 1172 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 2274 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2012 | 1640 | 0.060 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2008 | 476 | 0.060 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2014 | 1133 | 0.060 |
Why?
|
| Foreign-Body Migration | 1 | 2007 | 222 | 0.060 |
Why?
|
| Psychometrics | 1 | 2014 | 3002 | 0.060 |
Why?
|
| omega-Conotoxin GVIA | 2 | 1994 | 19 | 0.060 |
Why?
|
| Consensus | 3 | 2018 | 2959 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 5535 | 0.060 |
Why?
|
| Tennessee | 2 | 2015 | 117 | 0.060 |
Why?
|
| Quality of Life | 2 | 2016 | 12804 | 0.060 |
Why?
|
| Menopause | 1 | 2012 | 1626 | 0.060 |
Why?
|
| Hypotension | 1 | 2010 | 884 | 0.060 |
Why?
|
| Nutrition Surveys | 1 | 2010 | 1660 | 0.060 |
Why?
|
| Unconsciousness | 1 | 2005 | 263 | 0.060 |
Why?
|
| Republic of Korea | 2 | 2015 | 539 | 0.060 |
Why?
|
| Reoperation | 3 | 2012 | 4201 | 0.060 |
Why?
|
| Molecular Sequence Data | 12 | 2012 | 18111 | 0.060 |
Why?
|
| Computational Biology | 3 | 2021 | 3521 | 0.060 |
Why?
|
| Disabled Persons | 1 | 2013 | 1212 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2005 | 445 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2021 | 6256 | 0.050 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2022 | 26 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2005 | 880 | 0.050 |
Why?
|
| Histidine | 1 | 2023 | 313 | 0.050 |
Why?
|
| Emergency Service, Hospital | 2 | 2016 | 7659 | 0.050 |
Why?
|
| Selenocysteine | 1 | 2023 | 124 | 0.050 |
Why?
|
| Length of Stay | 1 | 2016 | 6309 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2020 | 2916 | 0.050 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2022 | 42 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2022 | 70 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 9856 | 0.050 |
Why?
|
| Nuclear Localization Signals | 1 | 2022 | 80 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Selenoproteins | 1 | 2023 | 216 | 0.050 |
Why?
|
| Cloning, Molecular | 6 | 1993 | 4320 | 0.050 |
Why?
|
| Risk | 4 | 2020 | 9687 | 0.050 |
Why?
|
| Genes, Reporter | 2 | 2018 | 1547 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4933 | 0.050 |
Why?
|
| Dihydropyridines | 2 | 1993 | 67 | 0.050 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 1343 | 0.050 |
Why?
|
| Arabs | 1 | 2023 | 178 | 0.050 |
Why?
|
| Actinin | 1 | 2022 | 160 | 0.050 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2023 | 1422 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2006 | 730 | 0.050 |
Why?
|
| Hospitalization | 4 | 2021 | 10262 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2024 | 893 | 0.050 |
Why?
|
| Population Control | 1 | 2020 | 20 | 0.050 |
Why?
|
| alpha Karyopherins | 1 | 2020 | 41 | 0.050 |
Why?
|
| Xenopus laevis | 2 | 2014 | 957 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2015 | 354 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2005 | 1850 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2007 | 1572 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 802 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1677 | 0.050 |
Why?
|
| Embryo, Nonmammalian | 2 | 2019 | 895 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2015 | 10252 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2021 | 106 | 0.050 |
Why?
|
| Cathepsin L | 1 | 2020 | 75 | 0.050 |
Why?
|
| Subcutaneous Tissue | 1 | 2021 | 135 | 0.050 |
Why?
|
| Population Density | 1 | 2021 | 196 | 0.050 |
Why?
|
| Iceland | 2 | 2013 | 183 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2015 | 3749 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2015 | 658 | 0.050 |
Why?
|
| Cardiac Myosins | 1 | 2020 | 117 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2023 | 528 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 2020 | 448 | 0.040 |
Why?
|
| Syncope | 2 | 2016 | 429 | 0.040 |
Why?
|
| Atlases as Topic | 1 | 2021 | 236 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2020 | 386 | 0.040 |
Why?
|
| Digestive System Diseases | 1 | 2021 | 147 | 0.040 |
Why?
|
| Rabbits | 3 | 1995 | 4894 | 0.040 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2021 | 338 | 0.040 |
Why?
|
| Phagocytes | 1 | 2021 | 297 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6538 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2021 | 528 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 2017 | 803 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 5391 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2014 | 3772 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2022 | 391 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 1 | 2019 | 206 | 0.040 |
Why?
|
| Exons | 2 | 2023 | 2437 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2020 | 365 | 0.040 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 414 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2023 | 1081 | 0.040 |
Why?
|
| Attitude | 1 | 2023 | 776 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 316 | 0.040 |
Why?
|
| Biological Transport | 1 | 2023 | 2118 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 673 | 0.040 |
Why?
|
| Smoking | 4 | 2019 | 8987 | 0.040 |
Why?
|
| Virulence | 1 | 2022 | 1333 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 2020 | 475 | 0.040 |
Why?
|
| Urogenital Abnormalities | 1 | 2021 | 261 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2005 | 2539 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2021 | 675 | 0.040 |
Why?
|
| Binding Sites | 2 | 2018 | 6114 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2011 | 3864 | 0.040 |
Why?
|
| Pericardiocentesis | 2 | 2008 | 74 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 549 | 0.040 |
Why?
|
| Injections | 1 | 2020 | 840 | 0.040 |
Why?
|
| Shal Potassium Channels | 1 | 2017 | 21 | 0.040 |
Why?
|
| Vitamin D | 1 | 2011 | 3223 | 0.040 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 1 | 2017 | 15 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 535 | 0.040 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2017 | 19 | 0.040 |
Why?
|
| Actomyosin | 1 | 2018 | 111 | 0.040 |
Why?
|
| Autopsy | 1 | 2021 | 1020 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2021 | 646 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 631 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13695 | 0.040 |
Why?
|
| Antihypertensive Agents | 2 | 2017 | 2046 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 6895 | 0.040 |
Why?
|
| RGS Proteins | 1 | 2017 | 77 | 0.040 |
Why?
|
| Genes | 1 | 2021 | 1893 | 0.040 |
Why?
|
| Gene Targeting | 1 | 2020 | 880 | 0.040 |
Why?
|
| Iodide Peroxidase | 1 | 2019 | 293 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 2019 | 494 | 0.040 |
Why?
|
| Gene Transfer Techniques | 2 | 2008 | 1224 | 0.040 |
Why?
|
| Neurons | 2 | 1993 | 9338 | 0.040 |
Why?
|
| Rats | 8 | 2012 | 24260 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2022 | 878 | 0.040 |
Why?
|
| Cell Movement | 2 | 2023 | 5217 | 0.040 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 55 | 0.040 |
Why?
|
| Neprilysin | 1 | 2019 | 439 | 0.040 |
Why?
|
| Insulin | 1 | 2011 | 6580 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 10943 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2022 | 1086 | 0.040 |
Why?
|
| ROC Curve | 2 | 2017 | 3527 | 0.040 |
Why?
|
| Somatomedins | 1 | 2017 | 192 | 0.040 |
Why?
|
| Antiporters | 1 | 2018 | 277 | 0.040 |
Why?
|
| Life Style | 2 | 2018 | 3835 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2023 | 964 | 0.030 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2018 | 315 | 0.030 |
Why?
|
| Proteins | 2 | 2017 | 6103 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 2020 | 791 | 0.030 |
Why?
|
| Exercise Test | 1 | 2024 | 2074 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2017 | 214 | 0.030 |
Why?
|
| Sarcomeres | 1 | 2018 | 374 | 0.030 |
Why?
|
| Electrochemistry | 1 | 1995 | 145 | 0.030 |
Why?
|
| Dogs | 1 | 2020 | 3912 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2019 | 502 | 0.030 |
Why?
|
| Cations, Divalent | 1 | 1995 | 166 | 0.030 |
Why?
|
| Blood Pressure | 3 | 2019 | 8554 | 0.030 |
Why?
|
| Research Report | 1 | 2019 | 355 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2021 | 855 | 0.030 |
Why?
|
| Genome | 1 | 2024 | 1808 | 0.030 |
Why?
|
| Morphogenesis | 1 | 2019 | 752 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2023 | 2751 | 0.030 |
Why?
|
| Interferon Regulatory Factors | 1 | 2017 | 270 | 0.030 |
Why?
|
| Benchmarking | 1 | 2022 | 1042 | 0.030 |
Why?
|
| Thyroxine | 1 | 2019 | 667 | 0.030 |
Why?
|
| Ion Transport | 1 | 2016 | 320 | 0.030 |
Why?
|
| Natural Language Processing | 1 | 2023 | 1041 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 1072 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2012 | 25625 | 0.030 |
Why?
|
| Thyrotoxicosis | 1 | 2015 | 82 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 1813 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 789 | 0.030 |
Why?
|
| DNA Replication | 1 | 2021 | 1399 | 0.030 |
Why?
|
| Medicare | 1 | 2012 | 6566 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2007 | 8324 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2010 | 4371 | 0.030 |
Why?
|
| Cell Communication | 1 | 2021 | 1621 | 0.030 |
Why?
|
| Manometry | 1 | 2016 | 445 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2020 | 1538 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2007 | 4042 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2020 | 1530 | 0.030 |
Why?
|
| omega-Agatoxin IVA | 1 | 1993 | 18 | 0.030 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5319 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 520 | 0.030 |
Why?
|
| Alcoholic Intoxication | 1 | 2015 | 188 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2016 | 3086 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2017 | 624 | 0.030 |
Why?
|
| Spider Venoms | 1 | 1993 | 44 | 0.030 |
Why?
|
| Electric Organ | 1 | 1993 | 54 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2017 | 835 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2018 | 2505 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2014 | 919 | 0.030 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2013 | 66 | 0.030 |
Why?
|
| Alanine | 1 | 1995 | 572 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2012 | 1990 | 0.030 |
Why?
|
| Cardiac Output, Low | 1 | 2014 | 195 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 9959 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 1889 | 0.030 |
Why?
|
| Point Mutation | 2 | 1995 | 1623 | 0.030 |
Why?
|
| Child | 3 | 2012 | 77709 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2021 | 1099 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2022 | 2107 | 0.030 |
Why?
|
| Septal Occluder Device | 1 | 2014 | 128 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2021 | 2488 | 0.030 |
Why?
|
| Cholesterol | 1 | 2022 | 2917 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 862 | 0.030 |
Why?
|
| Nickel | 1 | 1993 | 130 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 3760 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 976 | 0.030 |
Why?
|
| Glutamine | 1 | 1995 | 578 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2021 | 2902 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2014 | 537 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2016 | 1423 | 0.030 |
Why?
|
| Rats, Inbred BN | 1 | 2012 | 235 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1996 | 970 | 0.030 |
Why?
|
| Regeneration | 1 | 2021 | 1485 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 2012 | 377 | 0.030 |
Why?
|
| Viral Load | 1 | 2021 | 3299 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2012 | 475 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2016 | 952 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 783 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2013 | 791 | 0.030 |
Why?
|
| Inflammation | 3 | 2021 | 10638 | 0.030 |
Why?
|
| Arteries | 1 | 2016 | 1119 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2012 | 613 | 0.020 |
Why?
|
| Diabetes Mellitus | 3 | 2016 | 5751 | 0.020 |
Why?
|
| DNA Damage | 1 | 2021 | 2432 | 0.020 |
Why?
|
| Flurandrenolone | 1 | 2010 | 1 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 1741 | 0.020 |
Why?
|
| Acetanilides | 1 | 2012 | 168 | 0.020 |
Why?
|
| Myocardial Contraction | 2 | 2007 | 1585 | 0.020 |
Why?
|
| Prosencephalon | 1 | 1993 | 303 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 1114 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2012 | 862 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2014 | 853 | 0.020 |
Why?
|
| Transfection | 1 | 2019 | 5892 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 1993 | 400 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 658 | 0.020 |
Why?
|
| Aminophylline | 1 | 2010 | 40 | 0.020 |
Why?
|
| Papaverine | 1 | 2010 | 46 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 1602 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2005 | 9146 | 0.020 |
Why?
|
| Coronary Disease | 2 | 2019 | 6077 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 1058 | 0.020 |
Why?
|
| England | 1 | 2011 | 522 | 0.020 |
Why?
|
| Pericardial Effusion | 1 | 2012 | 247 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2011 | 187 | 0.020 |
Why?
|
| Drosophila | 1 | 2017 | 1491 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 35136 | 0.020 |
Why?
|
| Research Design | 1 | 2006 | 5987 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2915 | 0.020 |
Why?
|
| Atropine | 1 | 2010 | 244 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 1995 | 1169 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2019 | 6365 | 0.020 |
Why?
|
| Sleep | 1 | 2005 | 4623 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 1993 | 1137 | 0.020 |
Why?
|
| Phenobarbital | 1 | 2010 | 193 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 41006 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1832 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 2010 | 325 | 0.020 |
Why?
|
| Protein Conformation | 2 | 1994 | 4011 | 0.020 |
Why?
|
| RNA Interference | 1 | 2018 | 2889 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 2014 | 671 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2021 | 3690 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 2849 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2017 | 2263 | 0.020 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 1188 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 627 | 0.020 |
Why?
|
| COS Cells | 1 | 2010 | 1161 | 0.020 |
Why?
|
| Body Weight | 1 | 2019 | 4669 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 3505 | 0.020 |
Why?
|
| Acute Disease | 2 | 2011 | 7149 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2013 | 783 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2014 | 1147 | 0.020 |
Why?
|
| Boston | 2 | 2015 | 9313 | 0.020 |
Why?
|
| Potassium | 1 | 2012 | 1336 | 0.020 |
Why?
|
| Pacemaker, Artificial | 1 | 2014 | 816 | 0.020 |
Why?
|
| Netherlands | 1 | 2013 | 2170 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 4554 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 4462 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 3386 | 0.020 |
Why?
|
| Systems Biology | 1 | 2011 | 469 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 1814 | 0.020 |
Why?
|
| Health Surveys | 1 | 2018 | 4037 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2011 | 600 | 0.020 |
Why?
|
| Hong Kong | 1 | 2007 | 148 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 1991 | 934 | 0.020 |
Why?
|
| Health Care Costs | 2 | 2011 | 3209 | 0.020 |
Why?
|
| Rupture | 1 | 2008 | 433 | 0.020 |
Why?
|
| Receptors, GABA-A | 1 | 1991 | 627 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 8301 | 0.020 |
Why?
|
| North America | 1 | 2010 | 1249 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3870 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 804 | 0.020 |
Why?
|
| Community Health Services | 1 | 2011 | 650 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2014 | 1294 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2021 | 5102 | 0.020 |
Why?
|
| Electric Conductivity | 1 | 2007 | 411 | 0.020 |
Why?
|
| Central Nervous System | 1 | 1993 | 1357 | 0.020 |
Why?
|
| Angiotensin II | 1 | 2009 | 881 | 0.020 |
Why?
|
| Computer Systems | 1 | 2007 | 483 | 0.020 |
Why?
|
| Cardiac Tamponade | 1 | 2007 | 173 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2021 | 10481 | 0.020 |
Why?
|
| Coronary Vessels | 2 | 2007 | 3107 | 0.020 |
Why?
|
| Pericardium | 1 | 2010 | 667 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2019 | 12026 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2006 | 683 | 0.020 |
Why?
|
| Blotting, Northern | 3 | 1993 | 1581 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 2208 | 0.020 |
Why?
|
| Electrodes, Implanted | 1 | 2010 | 824 | 0.020 |
Why?
|
| Kinetics | 2 | 2009 | 6473 | 0.020 |
Why?
|
| Heart-Assist Devices | 1 | 2015 | 1194 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2020 | 7729 | 0.020 |
Why?
|
| Systems Integration | 1 | 2007 | 440 | 0.020 |
Why?
|
| Urban Population | 1 | 2013 | 2021 | 0.020 |
Why?
|
| Plakophilins | 1 | 2004 | 34 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 1959 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2010 | 944 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 969 | 0.020 |
Why?
|
| Sweden | 1 | 2007 | 1345 | 0.020 |
Why?
|
| Glucuronidase | 1 | 2005 | 207 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2008 | 1099 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 7913 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 2158 | 0.010 |
Why?
|
| Necrosis | 1 | 2008 | 1643 | 0.010 |
Why?
|
| Body Size | 1 | 2007 | 461 | 0.010 |
Why?
|
| Models, Animal | 1 | 2010 | 2171 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 4456 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2007 | 525 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2593 | 0.010 |
Why?
|
| Device Removal | 1 | 2008 | 656 | 0.010 |
Why?
|
| Reference Values | 1 | 2010 | 4982 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 2938 | 0.010 |
Why?
|
| Piperazines | 1 | 2012 | 2488 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2008 | 1265 | 0.010 |
Why?
|
| Overweight | 1 | 2013 | 2371 | 0.010 |
Why?
|
| Organ Size | 1 | 2007 | 2252 | 0.010 |
Why?
|
| Species Specificity | 1 | 2006 | 2478 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2011 | 2925 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 3068 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2012 | 8436 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 1889 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 4776 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 6773 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1992 | 2186 | 0.010 |
Why?
|
| Equipment Design | 1 | 2008 | 3582 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2010 | 2050 | 0.010 |
Why?
|
| Brain | 3 | 2011 | 26385 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2012 | 5317 | 0.010 |
Why?
|
| Dyspnea | 1 | 2006 | 1303 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2012 | 3114 | 0.010 |
Why?
|
| Swine | 1 | 2008 | 5917 | 0.010 |
Why?
|
| Artifacts | 1 | 2007 | 1904 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 7785 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1993 | 5708 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2014 | 11483 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 29144 | 0.010 |
Why?
|
| Nerve Endings | 1 | 1993 | 109 | 0.010 |
Why?
|
| Poly A | 1 | 1993 | 185 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 20822 | 0.010 |
Why?
|
| Ions | 1 | 1993 | 265 | 0.010 |
Why?
|
| Glutamates | 1 | 1993 | 398 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1993 | 590 | 0.010 |
Why?
|
| Affinity Labels | 1 | 1991 | 109 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14722 | 0.010 |
Why?
|
| Isomerism | 1 | 1991 | 201 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 878 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1991 | 374 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 1991 | 476 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6234 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1993 | 1454 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 708 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 427 | 0.010 |
Why?
|
| Clone Cells | 1 | 1993 | 1692 | 0.010 |
Why?
|
| Isoquinolines | 1 | 1991 | 367 | 0.010 |
Why?
|
| Multigene Family | 1 | 1993 | 1102 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1085 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 1996 | 3846 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1994 | 3129 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1993 | 2839 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 7880 | 0.010 |
Why?
|
| Motor Neurons | 1 | 1993 | 844 | 0.000 |
Why?
|
| Gene Library | 1 | 1990 | 1074 | 0.000 |
Why?
|
| Muscles | 1 | 1991 | 1614 | 0.000 |
Why?
|
| Phylogeny | 1 | 1993 | 2803 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6171 | 0.000 |
Why?
|
| RNA | 1 | 1993 | 2749 | 0.000 |
Why?
|
| Mitochondria | 1 | 1991 | 3520 | 0.000 |
Why?
|